The DOI matches its Crossref record; 109 of the 109 references it cites were found in a registry or an index.
New Treatment Addressing the Pathogenesis of Psoriasis
Open accessAbstract
Psoriasis is an immune cell-mediated inflammatory skin disease. The interleukin (IL)23/IL17 axis plays an important role in the development of psoriasis. The effectiveness of biologic treatments such as tumor necrosis factor (TNF)α inhibitors (infliximab, adalimumab, certolizumab pegol), IL23 inhibitors (ustekinumab, guselkumab, tildrakizumab, risankizumab), and IL17 inhibitors (secukinumab, ixekizumab, brodalumab) have verified these findings. Immune-related cells such as dendritic cells (DCs) and macrophages, in addition to Toll-like receptors and cytokines such as interferon (IFN)α, TNFα, IFNɤ, IL12, IL22, IL23, and IL17, are related to the pathogenesis of psoriasis. Here, we first review new insights regarding the pathogenesis of psoriasis, as it relates to DCs, Langerhans cells, macrophages, the signal transducer and activator of transcription 3 pathway, and aryl hydrocarbon receptor in cutaneous vascular endothelial cells. Based on these findings, we summarize currently available oral treatments and biologics. Furthermore, we describe a new treatment option including Janus kinase inhibitor, tyrosine kinase 2 inhibitor, modulator of sphingosine 1-phosphate receptor 1, and Rho-associated kinase 2 inhibitor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Korn, T., Bettelli, E., Oukka, M., & Kuchroo, V. K. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132710 · Cited by 4,873
Liang, S. C., Tan, X.-Y., Luxenberg, D. P., Karim, R., Dunussi-Joannopoulos, K., Collins, M., & Fouser, L. A. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061308 · Cited by 2,330
Pathogenesis and clinical features of psoriasis
Griffiths, C. E., & Barker, J. N. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61128-3 · Cited by 2,158
Psoriasis Pathogenesis and Treatment
Rendon, A., & Schäkel, K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061475 · Cited by 2,064
ROCKs: multifunctional kinases in cell behaviour
Riento, K., & Ridley, A. J. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1128 · Cited by 1,941
Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide
Lande, R., Gregorio, J., Facchinetti, V., Chatterjee, B., Wang, Y.-H., Homey, B., Cao, W., Wang, Y.-H., Su, B., Nestle, F. O., et al. (2007) · Nature · doi:10.1038/nature06116 · Cited by 1,910
Denison, M. S., & Nagy, S. R. (2003) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.43.100901.135828 · Cited by 1,895
The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention
O'Shea, J. J., Schwartz, D. M., Villarino, A. V., Gadina, M., McInnes, I. B., & Laurence, A. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-051113-024537 · Cited by 1,599
Generation of pathogenic TH17 cells in the absence of TGF-β signalling
Ghoreschi, K., Laurence, A., Yang, X.-P., Tato, C. M., McGeachy, M. J., Konkel, J. E., Ramos, H. L., Wei, L., Davidson, T. S., Bouladoux, N., et al. (2010) · Nature · doi:10.1038/nature09447 · Cited by 1,388
AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense
Lai, Y., & Gallo, R. L. (2009) · Trends in Immunology · doi:10.1016/j.it.2008.12.003 · Cited by 1,276
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
Schwartz, D. M., Kanno, Y., Villarino, A., Ward, M., Gadina, M., & O'Shea, J. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.201 · Cited by 1,266
Banerjee, S., Biehl, A., Gadina, M., Hasni, S., & Schwartz, D. M. (2017) · Drugs · doi:10.1007/s40265-017-0701-9 · Cited by 1,206
Plasmacytoid predendritic cells initiate psoriasis through interferon-α production
Nestle, F. O., Conrad, C., Tun-Kyi, A., Homey, B., Gombert, M., Boyman, O., Burg, G., Liu, Y.-J., & Gilliet, M. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050500 · Cited by 1,124
Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling
Eyerich, S., Eyerich, K., Pennino, D., Carbone, T., Nasorri, F., Pallotta, S., Cianfarani, F., Odorisio, T., Traidl-Hoffmann, C., Behrendt, H., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci40202 · Cited by 1,052
Psoriasis pathogenesis and the development of novel targeted immune therapies
Hawkes, J. E., Chan, T. C., & Krueger, J. G. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.07.004 · Cited by 972
The aryl hydrocarbon receptor: multitasking in the immune system
Stockinger, B., Meglio, P. D., Gialitakis, M., & Duarte, J. H. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120245 · Cited by 909
Sphingosine-1-Phosphate and Lymphocyte Egress from Lymphoid Organs
Cyster, J. G., & Schwab, S. R. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-075011 · Cited by 815
Frohm, M., Agerberth, B., Ahangari, G., Ståhle-Bäckdahl, M., Lidén, S., Wigzell, H., & Gudmundsson, G. H. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.24.15258 · Cited by 803
Chiricozzi, A., Guttman-Yassky, E., Suárez-Fariñas, M., Nograles, K. E., Tian, S., Cardinale, I., Chimenti, S., & Krueger, J. G. (2011) · Journal of Investigative Dermatology · doi:10.1038/jid.2010.340 · Cited by 686
Papp, K., Reich, K., Leonardi, C. L., Kircik, L., Chimenti, S., Langley, R. G. B., Hu, C., Stevens, R. M., Day, R. M., Gordon, K. B., et al. (2015) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.03.049 · Cited by 678
Santini, S. M., Lapenta, C., Logozzi, M., Parlato, S., Spada, M., Di Pucchio, T., & Belardelli, F. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.10.1777 · Cited by 643
Banerjee, S., Biehl, A., Gadina, M., Hasni, S., & Schwartz, D. M. (2017) · Drugs · doi:10.1007/s40265-017-0736-y · Cited by 590
The ‘psoriatic march’: a concept of how severe psoriasis may drive cardiovascular comorbidity
Boehncke, W.-H., Boehncke, S., Tobin, A.-M., & Kirby, B. (2011) · Experimental Dermatology · doi:10.1111/j.1600-0625.2011.01261.x · Cited by 530
Harper, E. G., Guo, C., Rizzo, H., Lillis, J. V., Kurtz, S. E., Skorcheva, I., Purdy, D., Fitch, E., Iordanov, M., & Blauvelt, A. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.65 · Cited by 508
The role of dendritic cells in autoimmunity
Ganguly, D., Haak, S., Sisirak, V., & Reizis, B. (2013) · Nature Reviews Immunology · doi:10.1038/nri3477 · Cited by 507
Collin, M., McGovern, N., & Haniffa, M. (2013) · Immunology · doi:10.1111/imm.12117 · Cited by 500
Pathogenesis of psoriasis and development of treatment
Ogawa, E., Sato, Y., Minagawa, A., & Okuyama, R. (2018) · The Journal of Dermatology · doi:10.1111/1346-8138.14139 · Cited by 456
S100 Proteins in the Epidermis
Eckert, R. L., Broome, A.-M., Ruse, M., Robinson, N., Ryan, D., & Lee, K. (2004) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2004.22719.x · Cited by 438
Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond
Kunkel, G. T., Maceyka, M., Milstien, S., & Spiegel, S. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4099 · Cited by 434
Bachelez, H., van de Kerkhof, P. C. M., Strohal, R., Kubanov, A., Valenzuela, F., Lee, J.-H., Yakusevich, V., Chimenti, S., Papacharalambous, J., Proulx, J., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62113-9 · Cited by 410
Mariette, X., Förger, F., Abraham, B., Flynn, A. D., Moltó, A., Flipo, R.-M., van Tubergen, A., Shaughnessy, L., Simpson, J., Teil, M., et al. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-212196 · Cited by 404
Tapinarof is a natural AhR agonist that resolves skin inflammation in mice and humans.
Smith, S. H., Jayawickreme, C., Rickard, D. J., Nicodeme, E., Bui, T., Simmons, C., Coquery, C. M., Neil, J., Pryor, W. M., Mayhew, D., et al. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2017.05.004 · Cited by 387
Angiogenesis drives psoriasis pathogenesis
Heidenreich, R., Röcken, M., & Ghoreschi, K. (2009) · International Journal of Experimental Pathology · doi:10.1111/j.1365-2613.2009.00669.x · Cited by 383
Melanocyte antigen triggers autoimmunity in human psoriasis
Arakawa, A., Siewert, K., Stöhr, J., Besgen, P., Kim, S.-M., Rühl, G., Nickel, J., Vollmer, S., Thomas, P., Krebs, S., et al. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20151093 · Cited by 361
Dendritic cell control of tolerogenic responses
Manicassamy, S., & Pulendran, B. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01015.x · Cited by 357
Papp, K. A., Menter, A., Strober, B., Langley, R. G., Buonanno, M., Wolk, R., Gupta, P., Krishnaswami, S., Tan, H., & Harness, J. A. (2012) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2012.11168.x · Cited by 338
Res, P. C. M., Piskin, G., de Boer, O. J., van der Loos, C. M., Teeling, P., Bos, J. D., & Teunissen, M. B. M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0014108 · Cited by 328
Papp, K. A., Menter, M. A., Abe, M., Elewski, B., Feldman, S. R., Gottlieb, A. B., Langley, R., Luger, T., Thaci, D., Buonanno, M., et al. (2015) · British Journal of Dermatology · doi:10.1111/bjd.14018 · Cited by 327
Scanning the Immunopathogenesis of Psoriasis
Chiricozzi, A., Romanelli, P., Volpe, E., Borsellino, G., & Romanelli, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010179 · Cited by 320
Emerging Topical and Systemic JAK Inhibitors in Dermatology
Solimani, F., Meier, K., & Ghoreschi, K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02847 · Cited by 308
Inhibition of the Interleukin-36 Pathway for the Treatment of Generalized Pustular Psoriasis
Bachelez, H., Choon, S.-E., Marrakchi, S., Burden, A. D., Tsai, T.-F., Morita, A., Turki, H., Hall, D. B., Shear, M., Baum, P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmc1811317 · Cited by 292 · cited 2×
“In the phase 1 clinical trial, an intravenous single dose of BI 655130, a monoclonal antibody against the interleukin-36 receptor showed good efficacy regardless of the presence of the IL36RN mutation over a 20-week period [83].”
BackgroundMacri, C., Pang, E. S., Patton, T., & O’Keeffe, M. (2018) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2017.12.009 · Cited by 275
Zanin-Zhorov, A., Weiss, J. M., Nyuydzefe, M. S., Chen, W., Scher, J. U., Mo, R., Depoil, D., Rao, N., Liu, B., Wei, J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1414189111 · Cited by 262
Psoriasin: A Novel Chemotactic Protein
Jinquan, T., Vorum, H., Larsen, C. G., Madsen, P., Rasmussen, H. H., Gesser, B., Etzerodt, M., Honoré, B., Celis, J. E., & Thestrup-Pedersen, K. (1996) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12294284 · Cited by 239
Antimicrobial peptides in the pathogenesis of psoriasis
MORIZANE, S., & GALLO, R. L. (2012) · The Journal of Dermatology · doi:10.1111/j.1346-8138.2011.01483.x · Cited by 237
Biswas, P. S., Gupta, S., Chang, E., Song, L., Stirzaker, R. A., Liao, J. K., Bhagat, G., & Pernis, A. B. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42856 · Cited by 236
Immunocompetent cells in psoriasis: In situ immunophenotyping by monoclonal antibodies
Bos, J. D., Hulsebosch, H. J., Krieg, S. R., Bakker, P. M., & Cormane, R. H. (1983) · Archives of Dermatological Research · doi:10.1007/bf00510050 · Cited by 236
Morizane, S., Yamasaki, K., Mühleisen, B., Kotol, P. F., Murakami, M., Aoyama, Y., Iwatsuki, K., Hata, T., & Gallo, R. L. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2011.259 · Cited by 234
Psoriatic scales: a promising source for the isolation of human skin-derived antimicrobial proteins
Harder, J., & Schröder, J.-M. (2005) · Journal of Leukocyte Biology · doi:10.1189/jlb.0704409 · Cited by 228
Flynn, R., Paz, K., Du, J., Reichenbach, D. K., Taylor, P. A., Panoskaltsis-Mortari, A., Vulic, A., Luznik, L., MacDonald, K. K. P., Hill, G. R., et al. (2016) · Blood · doi:10.1182/blood-2015-10-678706 · Cited by 227
Hänsel, A., Günther, C., Ingwersen, J., Starke, J., Schmitz, M., Bachmann, M., Meurer, M., Rieber, E. P., & Schäkel, K. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.12.009 · Cited by 223
Plasmacytoid dendritic cells: key players in the initiation and regulation of immune responses
Lande, R., & Gilliet, M. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05152.x · Cited by 220
Aryl Hydrocarbon Receptor in Atopic Dermatitis and Psoriasis
Furue, M., Hashimoto-Hachiya, A., & Tsuji, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215424 · Cited by 215
Ramirez, J., Brembilla, N. C., Sorg, O., Chicheportiche, R., Matthes, T., Dayer, J., Saurat, J., Roosnek, E., & Chizzolini, C. (2010) · European Journal of Immunology · doi:10.1002/eji.201040461 · Cited by 189
Singh, T. P., Zhang, H. H., Borek, I., Wolf, P., Hedrick, M. N., Singh, S. P., Kelsall, B. L., Clausen, B. E., & Farber, J. M. (2016) · Nature Communications · doi:10.1038/ncomms13581 · Cited by 180
2-Imino-thiazolidin-4-one Derivatives as Potent, Orally Active S1P1Receptor Agonists
Bolli, M. H., Abele, S., Binkert, C., Bravo, R., Buchmann, S., Bur, D., Gatfield, J., Hess, P., Kohl, C., Mangold, C., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100181s · Cited by 179
Highly Effective New Treatments for Psoriasis Target the IL-23/Type 17 T Cell Autoimmune Axis
Kim, J., & Krueger, J. G. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-042915-103905 · Cited by 174
Innate immunity and antimicrobial defense systems in psoriasis
Büchau, A. S., & Gallo, R. L. (2007) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2007.08.016 · Cited by 169
Cho, K., Suh, J. W., Lee, K. H., Kang, J. L., & Woo, S. (2011) · International Immunology · doi:10.1093/intimm/dxr110 · Cited by 161
Cationic antimicrobial peptides in psoriatic skin cooperate to break innate tolerance to self‐DNA
Lande, R., Chamilos, G., Ganguly, D., Demaria, O., Frasca, L., Durr, S., Conrad, C., Schröder, J., & Gilliet, M. F. (2014) · European Journal of Immunology · doi:10.1002/eji.201344277 · Cited by 157
Regulatory dendritic cells in autoimmunity: A comprehensive review
Liu, J., & Cao, X. (2015) · Journal of Autoimmunity · doi:10.1016/j.jaut.2015.07.011 · Cited by 155
Vaclavkova, A., Chimenti, S., Arenberger, P., Holló, P., Sator, P.-G., Burcklen, M., Stefani, M., & D’Ambrosio, D. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60803-5 · Cited by 154
Richardson, W. H., Schmidt, T. M., & Nealson, K. H. (1988) · Applied and Environmental Microbiology · doi:10.1128/aem.54.6.1602-1605.1988 · Cited by 153
Bissonnette, R., Iversen, L., Sofen, H. L., Griffiths, C. E. M., Foley, P. A., Romiti, R., Bachinsky, M., Rottinghaus, S. T., Tan, H., Proulx, J., et al. (2014) · British Journal of Dermatology · doi:10.1111/bjd.13551 · Cited by 151
Dendritic cells: The driver of psoriasis
Wang, A., & Bai, Y. (2019) · The Journal of Dermatology · doi:10.1111/1346-8138.15184 · Cited by 143
Maza, A., Montaudié, H., Sbidian, É., et al. (2011) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2011.03992.x · Cited by 135
Sphingosine 1-Phosphate Receptor Modulators and Drug Discovery
Park, S.-J., & Im, D. (2016) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2016.160 · Cited by 132
Manggau, M. A., Kim, D.-S., Ruwisch, L., Vogler, R., Schäfer-Korting, M., Kleuser, B., & Körting, H. C. (2001) · Journal of Investigative Dermatology · doi:10.1046/j.0022-202x.2001.01496.x · Cited by 130
Pandya, V. B., Kumar, S., Sachchidanand, Sharma, R. K., & Desai, R. C. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00588 · Cited by 130
Fuentes‐Duculan, J., Bonifacio, K. M., Hawkes, J. E., Kunjravia, N., Cueto, I., Li, X., Gonzalez, J., Garcet, S., & Krueger, J. G. (2017) · Experimental Dermatology · doi:10.1111/exd.13378 · Cited by 129
Selective ROCK 2 inhibition in focal cerebral ischemia
Lee, J. H., Zheng, Y. Z., von Bornstaedt, D., Wei, Y. J., Balcioglu, A., Daneshmand, A., Yalcin, N., Yu, E. S., Hérisson, F., Atalay, Y. B., et al. (2013) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.19 · Cited by 124
Vogler, R., Sauer, B., Kim, D.-S., Schäfer‐Korting, M., & Kleuser, B. (2003) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2003.12096.x · Cited by 123
Terhorst‐Molawi, D., Chelbi, R., Wohn, C., Malosse, C., Tamoutounour, S., Jorquera, A., Bajénoff, M., Dalod, M., MALISSEN, B., & Henri, S. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500551 · Cited by 116
The role of epidermal sphingolipids in dermatologic diseases
Borodzicz-Jażdżyk, S., Rudnicka, L., Mirowska-Guzel, D. M., & Cudnoch‐Jędrzejewska, A. (2016) · Lipids in Health and Disease · doi:10.1186/s12944-016-0178-7 · Cited by 112
Piali, L., Froidevaux, S., Hess, P., Nayler, O., Bolli, M. H., Schlosser, E., Kohl, C., Steiner, B., & Clozel, M. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.176487 · Cited by 110
Ueyama, A., Yamamoto, M., Tsujii, K., Furue, Y., Imura, C., Shichijo, M., & Yasui, K. (2014) · The Journal of Dermatology · doi:10.1111/1346-8138.12367 · Cited by 108
Robbins, K., Bissonnette, R., Maeda‐Chubachi, T., Ye, L., Peppers, J., Gallagher, K., & Kraus, J. E. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.10.037 · Cited by 108
D’Ambrosio, D., Freedman, M. S., & Prinz, J. C. (2016) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622315617354 · Cited by 105
Zanin‐Zhorov, A., Weiss, J. M., Trzeciak, A. J., Chen, W., Zhang, J., Nyuydzefe, M. S., Arencibia, C., Polimera, S., Schueller, O. J. A., Fuentes‐Duculan, J., et al. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1602142 · Cited by 98
Papp, K. A., Leonardi, C., Blauvelt, A., Reich, K., Korman, N., Ohtsuki, M., Paul, C. F., Ball, S. G., Cameron, G. S., Erickson, J., et al. (2017) · British Journal of Dermatology · doi:10.1111/bjd.16050 · Cited by 97
Zhang, J., Tsai, T., Lee, M., Zheng, M., Wang, G., Jin, H., Gu, J., Li, R.-Y., Liu, Q., Jin, C., et al. (2017) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2017.05.004 · Cited by 90
Schüppel, M., Kürschner, U., Kleuser, U., Schäfer‐Korting, M., & Kleuser, B. (2008) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5701259 · Cited by 89
Martini, E., Wikén, M., Cheuk, S., Sérézal, I. G., Baharom, F., Ståhle, M., Smed‐Sörensen, A., & Eidsmo, L. (2016) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.11.033 · Cited by 86
Ganesan, R., Raymond, E. L., Mennerich, D., Woska, J. R., Caviness, G. O., Grimaldi, C. M., Ahlberg, J., Perez, R., Roberts, S., Yang, D., et al. (2017) · mAbs · doi:10.1080/19420862.2017.1353853 · Cited by 86
Takagi, H., Arimura, K., Uto, T., Fukaya, T., Nakamura, T., Choijookhuu, N., Hishikawa, Y., & Sato, K. (2016) · Scientific Reports · doi:10.1038/srep24477 · Cited by 84
Brodalumab in psoriasis: evidence to date and clinical potential
Foulkes, A., & Warren, R. B. (2019) · Drugs in Context · doi:10.7573/dic.212570 · Cited by 81
Auriemma, M., Brzoska, T., Klenner, L., Kupas, V., Goerge, T., Voskort, M., Zhao, Z., Sparwasser, T. D., Luger, T. A., & Loser, K. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.59 · Cited by 76
Plasmacytoid dendritic cells in autoimmunity
Panda, S. K., Kolbeck, R., & Sanjuán, M. A. F. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.10.006 · Cited by 72
Tang, L., Yang, X. T., Liang, Y., Xie, H., Dai, Z., & Zheng, G. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01210 · Cited by 69
Schaper, K., Dickhaut, J., Japtok, L., Kietzmann, M., Mischke, R., Kleuser, B., & Bäumer, W. (2013) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2013.03.006 · Cited by 68
RNase 7 Strongly Promotes TLR9-Mediated DNA Sensing by Human Plasmacytoid Dendritic Cells
Kopfnagel, V., Wagenknecht, S., Harder, J., Hofmann, K., Kleine, M., Buch, A., Sodeik, B., & Werfel, T. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2017.09.052 · Cited by 65
Tohyama, M., Yang, L., Hanakawa, Y., Dai, X., Shirakata, Y., & Sayama, K. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2011.468 · Cited by 64
To fingolimod and beyond: The rich pipeline of drug candidates that target S1P signaling
Chew, W. S., Wang, W., & Herr, D. R. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.09.025 · Cited by 64
Blauvelt, A., Sofen, H. L., Papp, K. A., Gooderham, M., Tyring, S. K., Zhao, Y., Lowry, S., Mendelsohn, A. B., Parno, J. R., & Reich, K. (2019) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.15862 · Cited by 60
Zhu, Z., Chen, J., Lin, Y., Zhang, C., Li, W., Qiao, H., Fu, M., Dang, E., & Wang, G. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2019.11.022 · Cited by 57
Guselkumab for the treatment of psoriasis – evidence to date
Nogueira, M., & Torres, T. R. (2019) · Drugs in Context · doi:10.7573/dic.212594 · Cited by 54
Th17 Cells Carrying TCR Recognizing Epidermal Autoantigen Induce Psoriasis-like Skin Inflammation
Nishimoto, S., Kotani, H., Tsuruta, S., Shimizu, N., Ito, M., Shichita, T., Morita, R., Takahashi, H., Amagai, M., & Yoshimura, A. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300348 · Cited by 49
Yamanaka, K., & Mizutani, H. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.06.009 · Cited by 48
Infliximab for the treatment of plaque psoriasis
Kalb, R. E. (2008) · Biologics · doi:10.2147/btt.s2116 · Cited by 47
Eaton, L. H., Mellody, K. T., Pilkington, S. M., Dearman, R. J., Kimber, I., & Griffiths, C. E. M. (2017) · British Journal of Dermatology · doi:10.1111/bjd.16172 · Cited by 41
Blauvelt, A., Reich, K., Lebwohl, M., Burge, D. J., Arendt, C. H., Peterson, L., Drew, J., Rolleri, R. L., & Gottlieb, A. B. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.15258 · Cited by 38
Binding Affinity and Interaction of LL-37 with HLA-C*06:02 in Psoriasis
Mabuchi, T., & Hirayama, N. (2016) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.04.033 · Cited by 35
Self-citationDiscovery of super soft-drug modulators of sphingosine-1-phosphate receptor 1
Bell, M. E., Foley, D., Naylor, C., Robinson, C., Riley, J., Epemolu, O., Scullion, P., Shishikura, Y., Katz, E., McLean, W. H. I., et al. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.07.044 · Cited by 26
Imura, C., Ueyama, A., Sasaki, Y., et al. (2019) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2019.03.002 · Cited by 26
Secukinumab (AIN457) for the treatment of psoriasis
López‐Ferrer, A., Vilarrasa, E., & Puig, L. (2015) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2015.1095092 · Cited by 23
Validating a Selective S1P1 Receptor Modulator Syl930 for Psoriasis Treatment
Ji, M., Xue, N., Lai, F., Zhang, X., Zhang, S., Wang, Y., Jin, J., & Chen, X. (2018) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b17-00939 · Cited by 23
Witjes, H., Khatri, A., Diderichsen, P. M., Mandema, J. W., & Othman, A. A. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1624 · Cited by 19
Modeling clinical efficacy of the S1P receptor modulator ponesimod in psoriasis
Krause, A., D’Ambrosio, D., & Dingemanse, J. (2017) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2017.11.003 · Cited by 16
More tolerance for dendritic cells in psoriasis
Buhl, T., Saleh, M. M., & Schön, M. P. (2016) · Experimental Dermatology · doi:10.1111/exd.13153 · Cited by 9
Cited by
Targeting sphingosine-1-phosphate signaling in immune-mediated diseases: beyond multiple sclerosis
Pérez-Jeldres, T., Alvarez-Lobos, M., & Rivera-Nieves, J. (2021) · Drugs · doi:10.1007/s40265-021-01528-8 · Cited by 197
Metadata
- Authors
- Tokuyama, M., & Mabuchi, T.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-10-11
- Volume
- 21
- Issue
- 20
- Pages
- 7488
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3092092411
- Cited by
- 291
- References
- 109
- FWCI
- 8.45
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.